You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Customer discovery for minimally invasive nerve block device to treat severe pain and reduce usage of opiates

    SBC: Thermaquil, Inc.            Topic: 106

    Abstract: Thoracotomy is one of the most painful surgical procedures and patients are at high risk of developing opioid addiction. Recent studies have shown 1 in 7 patients became new persistent opioid users after physical recovery from the surgery was complete. The largest risk factor for opioid addiction is being prescribed opioids in the first place, and Thermaquil wants to reduce this incidenc ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Prevention of renarcotization from synthetic opioids

    SBC: Consegna Pharma Inc.            Topic: NIDA

    PROJECT SUMMARY/ABSTRACT In October 2017, the U.S. Government declared the current opioid epidemic the worst drug crisis in American history. Synthetically derived opioids such as fentanyl and fentanyl-derivatives have been at the forefront of this public health emergency, exhibiting the highest year-to-year contribution to overdose deaths. While the mu opioid receptor (MOR) antagonist naloxone ha ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. LystaMab Immunotherapy to Inhibit Pericardial Adhesions

    SBC: Lyst Therapeutics LLC            Topic: NHLBI

    SUMMARY Despite significant advances in the surgical and medical management of congenital heart diseasecongenital cardiac anomalies remain a leading cause of death in the newborn periodMost severe forms of congenital heart disease require multiplestaged surgical interventionsA significant source of the heightened morbidity and mortality associated with these operations is the development of cardia ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based

    SBC: KLEIN BUENDEL, INC            Topic: 102

    Project Summary While studies support the efficacy of comprehensiveschool wide interventions in reducing bullyingthese types of programs can require significant time and financial resources for implementationresulting in barriers to providing school based bullying preventionespecially in low income and rural communitiesAdditionallyalthough training bystanders to act asdefenderson behalf of targets ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Optimizing Usability of the Orally Rehydrate Children at Home Mobile Application- Optimize ORCAH

    SBC: Data2Care Technologies, LLC            Topic: NICHD

    Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.

    SBC: Oncoimmune Inc            Topic: 100

    Project Summary AbstractThe recent rapid expansion of genomic data greatly contributes to the understanding of disease development and progressionTo translate these genetic discoveries into clinical applicationswe need to develop therapeutic platforms that can specifically modulate the expression of disease related genes in vivoSmall RNAssuch as microRNAs and siRNAs function in messenger RNA silen ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Associating Clinical Decision Support Use with Clinical Outcomes in a Visual Analytics Display

    SBC: PHRASE Health, INC.            Topic: NLM

    Project Summary Abstract Clinical decision supportCDSis a process for enhancing health related decisions and actions with pertinentorganized clinical knowledge and patient information to improve healthcare deliveryFor exampledoctors may have trouble remembering to order all guideline recommended care for sepsisCDS delivered via an order set in the electronic health recordEHRcan simplify this proce ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Small-molecule combinationsexpand hematopoietic stem cell ex vivo and in vivo

    SBC: Advac Therapeutic LLC            Topic: NHLBI

    Small-molecule combinations expand hematopoietic stem cell ex vivo and in vivo Abstract Hematopoietic stem cells (HSCs) are featured by their self-renewal potential and ability to differentiate into multiple blood lineages. Hematopoietic stem cell transplant (HSCT) is a mainstay of life-saving therapy for hematopoietic malignancies and hypoproliferative disorders. The use of noninvasively accessib ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.

    SBC: BIOMIMETIX JV LLC            Topic: 102

    Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government